Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Sci. Signal., 5 July 2011
Vol. 4, Issue 180, p. ra44
Targeting Lysosomes to Limit Inflammation
Chloroquine, which inhibits lysosome function, is best known for its use as an antimalarial agent. However, it has also been clinically used to treat inflammation. He et al. showed that agents that inhibit lysosome function or biogenesis promoted glucocorticoid-mediated regulation of gene expression and that this enhancement of glucocorticoid signaling was associated with an increase in the stability and abundance of the glucocorticoid receptor. Other receptors of the nuclear receptor family, but not other transcription factors, were also stabilized by inhibition of lysosomal function, suggesting that a lysosomal pathway contributes to the degradation of this family of receptors and may present a target for development of treatment strategies for autoimmune and inflammatory diseases, as well as diseases associated with aberrant nuclear receptor signaling.
Citation: Y. He, Y. Xu, C. Zhang, X. Gao, K. J. Dykema, K. R. Martin, J. Ke, E. A. Hudson, S. K. Khoo, J. H. Resau, A. S. Alberts, J. P. MacKeigan, K. A. Furge, H. E. Xu, Identification of a Lysosomal Pathway That Modulates Glucocorticoid Signaling and the Inflammatory Response. Sci. Signal.4, ra44 (2011).
Rosetta Merline, Kristin Moreth, Janet Beckmann, Madalina V. Nastase, Jinyang Zeng-Brouwers, José Guilherme Tralhão, Patricia Lemarchand, Josef Pfeilschifter, Roland M. Schaefer, Renato V. Iozzo, and Liliana Schaefer (15 November 2011) Sci. Signal.4 (199), ra75.
[DOI: 10.1126/scisignal.2001868] |Editor's Summary »|Abstract »|Full Text »|PDF »|Supplementary Materials »